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Background: The immune system reconstitution in HIV-1- infected patients undergoing combined antiretroviral
therapy is routinely evaluated by T-cell phenotyping, even though the infection also impairs the B-cell mediated
immunity. To find new laboratory markers of therapy effectiveness, both B- and T- immune recovery were
evaluated by means of a follow-up study of long-term treated HIV-1- infected patients, with a special focus on the
measure of new B- and T-lymphocyte production.
Methods: A longitudinal analysis was performed in samples obtained from HIV-1-infected patients before therapy
beginning and after 6, 12, and 72 months with a duplex real-time PCR allowing the detection of K-deleting
recombination excision circles (KRECs) and T-cell receptor excision circles (TRECs), as measures of bone-marrow and
thymic output, respectively. A cross sectional analysis was performed to detect B- and T-cell subsets by flow
cytometry in samples obtained at the end of the follow-up, which were compared to those of untreated
HIV-1-infected patients and uninfected controls.
Results: The kinetics and the timings of B- and T-cell release from the bone marrow and thymus during
antiretroviral therapy were substantially different, with a decreased B-cell release and an increased thymic output
after the prolonged therapy. The multivariable regression analysis showed that a longer pre-therapy infection
duration predicts a minor TREC increase and a major KREC reduction.
Conclusions: The quantification of KRECs and TRECs represents an improved method to monitor the effects of
therapies capable of influencing the immune cell pool composition in HIV-1-infected patients.
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Although CD4+ T cells are the major target of HIV-1, this
infection widely impairs the viability and function of
numerous other immune cells [1]. In particular, in the
absence of therapy, HIV-1 infection is associated with
several B-cell defects, including polyclonal hypergamma-
globulinemia [2], modified expression of activation and
costimulatory markers [3-6], decreased B-cell survival
[7,8], and the presence of exhausted terminally differen-
tiated B cells or CD27- memory B cells [9-11].* Correspondence: limberti@yahoo.it
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distribution, and reproduction in any mediumFurthermore, recent results showed that HIV-1 infection
not only induces a strong depletion in memory B cells,
but is also associated with defects in the naive B-cell sub-
set [12].
Combined antiretroviral therapy (cART) is very effi-
cient in reducing HIV-1 load and, currently, even with
salvage therapy, up to 90% of treated HIV-1-infected
adults attain viral RNA plasma levels under the limit of
detection of commercially available tests [13]. As a con-
sequence of the viral suppression, resulting into a grad-
ual reprise of thymic output, the CD4+ cell count
reaches normal levels in most but not all treated patients
[14]. Still, in some of them, the T-cell recovery remains
abnormally low in spite of the complete suppression ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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progression and death [15-17]. Therefore, one of the
problems in the field of anti-viral therapy in HIV-1-
infected patients is how to achieve an efficient monitor-
ing of the immune reconstitution following cART. Rou-
tinely, the immune system restoration is evaluated by
T-cell phenotyping. A more specific way to measure the
recovery of the immune system is the quantification of
the recent thymic emigrants (RTE) that are CD4+ lym-
phocytes expressing the CD45RA and CD31 markers or
harbouring the T-cell receptor excision circles (TRECs),
which are extrachromosomic circular DNA episomes
produced during T-cell receptor rearrangement. TRECs,
in particular, have been used as a surrogate marker of
thymic output [18]. While TREC number in HIV-1-
infected patients has been found to correlate with differ-
ent clinical-pathological parameters (age, plasma HIV-1
RNA, CD4+ T-lymphocyte counts, CD4+ T-lymphocyte
percentages, and naive CD4+ T-lymphocyte number)
and TREC number of HIV-1-infected children increases
during cART [19-22], to our knowledge, no studies have
investigated the effects of cART treatment on the release
of new B lymphocytes from the bone marrow of treated
patients. Moreover, it is not known whether the recovery
of B and T cells occurs simultaneously. Therefore, here,
the effect of cART on the mobilization of new B and T
cells during a long follow-up (72 months) was analyzed
by a duplex real-time PCR that combines the measure of
TRECs with the quantification of the “K deleting recom-
bination excision circles” (KRECs) that assesses the ex-
tent of the B-cell output [23,24]. Real-time PCR was also
used to quantify the mRNA expression of interleukin 7
(IL-7) and of the alpha chain of IL-7 receptor (IL-7Rα),
while flow cytometry was used to evaluate the cell sur-
face expression of IL-7Rα on CD4+ cells and the modu-
lation of B- and T-cell subsets.
Methods
Participants and study design
Thirty-six HIV-1-infected adult patients (group I), en-
rolled by the Institute of Infectious and Tropical Dis-
eases of University of Brescia (Italy) during the
SImplified Sequencing THERapy trial (SI.S.THER.), par-
ticipated to this study. SI.S.THER. was a 12 months long
multicentre prospective randomized trial, in which HIV+
patients who had never been treated before, but requir-
ing antiretroviral therapy according to the current guide-
lines for the use of antiretroviral therapy, were randomly
assigned, in a one-to-one ratio, to receive either zidovu-
dine + lamivudine + lopinavir/ritonavir or tenofovir +
lamivudine + efavirenz [25]. Peripheral blood mono-
nuclear cells (PBMCs), prepared by Ficoll-Hypaque
density gradient centrifugation, were obtained from the
blood of these patients before therapy initiation (T0),after 6 (T6) and 12 (T12) months, and then stored and
used for laboratory analysis. A further blood sample was
obtained after 6 years of antiretroviral therapy (T72).
The routine clinical examination, CD4+ T-cell count,
and HIV-1 RNA quantification were assessed at all time
points. A first control group (group II) consisted of 22
randomly selected HIV-1-infected patients who were
regularly followed up in the HIV outpatient clinic, but
did not need antiretroviral therapy according to the
current guidelines. HIV-uninfected persons, matched by
age and gender with the patients of group I in a two-to-
one ratio, were selected as a second control group
(group III). Only one blood sample was obtained from
individuals of group II and III. The baseline characteris-
tics of patients of group I and II and the immuno-
virological features observed during the follow-up in
group I are summarized in Table 1.
The study was conducted in accordance with good
clinical practice (ICH-E6). The trial and amendments
received approval by the institutional review board/inde-
pendent ethics committee (resolution of n° 33 of March
11, 2011) and the patients provided written informed
consent before the SI.S.THER. trial and for the present
study as well.
Real-time PCR for KRECs, TRECs, IL-7 and IL-7Rα
quantification
DNA was extracted from about 3 × 106 PBMCs using
the QIAamp DNA Blood Mini Kit (Qiagen, Valencia,
CA), according to the manufacturer’s instructions. KREC
and TREC molecules were detected by a duplex quanti-
tative real-time PCR, in which the simultaneous amplifi-
cation of the two target sequences occurs in a single
reaction, and the specific probes, labeled with different
fluorescent dyes, allowed to separately quantify the
amount of each target. The sequence of primers and
probes for the signal joint regions of KRECs and TRECs,
as well as for the reference gene, which was a fragment
of the T-cell receptor alpha constant gene (TCRAC),
have been previously described [23]. The PCR reactions
were developed in 96-well optical reaction plates (Ap-
plied Biosystems, Foster City, CA) and the reaction mix-
ture was prepared in a total volume of 25 μL containing
12.5 μL of 2x TaqMan Universal PCR master mix con-
taining AmpErase UNG (Applied Biosystems), 900 nM
forward and reverse primers, 200 nM probes, and 5 μL
of genomic DNA solution. Amplification of the TCRAC
was done in the same plate. The conditions for the real-
time PCR, performed on a 7500 Fast Real-Time PCR
System (Applied Biosystems), were 50°C for 2 minutes
and 95°C for 10 minutes, followed by 45 cycles of 95°C
for 15 seconds and 60°C for 1 minute. All samples were
measured in duplicate. The number of KREC, TREC and
TCRAC molecules in the sample was extrapolated by
Table 1 Baseline characteristics of HIV-1+ patients
Group I Group II p -value*
T0 T6 T12 T72
Males 32 (88.9) - - - 17 (77.3) -
Age (years) 39 (35–45) - - - 38 (33–43) -
Risk factors for HIV-1:
 Heterosexual 20 (55.6) - - - 7 (31.8) -
 Homo/bisexual 10 (27.8) - - - 10 (45.5) -
 IVDU 3 (8.3) - - - 5 (22.7) -
Other/unknown 3 (8.3) - - - 0 (0) -
CD4+ T cells (cells/μL) 258 (139–331) 377 (225–505) 419 (247–570) 688 (407–822) 538 (455–691) <0.0001
CD8+ T cells (cells/μL) 754 (637–1338) 781 (598–990) 753 (561–983) 707 (598–805) 757 (595–1138) -
CD4+/CD8+ T-cell ratio 0.3 (0.2–0.4) 0.5 (0.3–0.7) 0.6 (0.4–0.7) 0.8 (0.6–1.1) 0.7 (0.5–1) <0.0001
HIV-1 RNA (copies/mL) 74533 (21264–196233) < 50 (50–50) < 50 (50–50) < 37 (37–37) 14155 (263–33380) <0.01
For continuous variables the medians (interquartile ranges) are shown, while for categorical variables the number (percentage) is shown.
Group I, HIV-1-infected patients enrolled in the SI.S.THER. study; group II, HIV-1-infected patients naive to antiretroviral therapy.
IVDU indicates Intravenous Drug Users.
*p -value of the comparison between group I at T0 and group II.
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104, 103, 102, and 10) of a linearized plasmid DNA, con-
taining three inserts corresponding to fragments of
KRECs, TRECs and TCRAC, which were amplified in
each PCR plate. KREC and TREC copies were calculated
per mL of blood by multiplying the number of KREC or
TREC molecules in the sample by the lymphocyte plus
monocyte count per mL of blood, as done by Chen et al.
[26]. The quantity of TRECs per 106 PBMC was also
reported, and their density per naive cells or per RTE
cells was calculated dividing the value of TRECs/mL by
the numbers of naive T cells/mL or RTE cells/mL.
One hundred and fifty ng of total RNA, extracted from
PBMCs using NucleoSpin RNA II kit (Macherey-Nagel
GmbH & Co. KG, Düren, Germany) were reverse tran-
scribed into cDNA using random hexamers and Taqman
reverse transcription reagents (Applied Biosystems). An
equivalent of 22.5 ng of RNA was analyzed in each well
on the 7500 Fast Real-Time PCR System using TaqMan
Gene Expression Assay for IL-7 and IL-7Rα, (IL-7:
Hs00174202_m1 and IL-7R: Hs00902334_m1; Applied
Biosystems) or primers and probe for glyceraldehyde 3-
phosphate-dehydrogenase (GAPDH: forward primer:
50GAAGGTGAAGGTCGGAGTC30, reverse primer:
50GAAGATGGTGATGGGATTTC30 and probe: Fam-
CAAGCTTCCCGTTCTCAGCC-Tamra) synthesized
according to the Applied Biosystems recommendations.
Results, obtained using the comparative Cycle threshold
(Ct) method with GAPDH as the reference gene and
the RNA extracted from the pooled PBMCs of 10
healthy donors as the calibrator sample, were reported
as the value of “– ΔΔCt”, being ΔΔCt = [(Ct target –
Ct reference gene) patient – (Ct target – Ct reference
gene) calibrator].Cytofluorimetric characterization of lymphocyte
subpopulations and IL-7Rα analysis
B- and T-cell subsets were determined by six-colour
flow cytometry analysis on the fresh whole blood
obtained at T72 from group I patients and from both
group II and III control individuals. Briefly, for the
identification of B-cell subsets, 100 μL of whole blood
was stained with various combinations of optimal
staining concentrations (previously determined by titra-
tions) of peridin-clorophyll protein-Cy5.5 anti-CD19,
phycoerythtin-Cy7 anti-CD10, fluorescein isothiocyanate
anti-IgD, and phycoerythrin anti-CD27 (BD Pharmingen,
Heidelberg, Germany) monoclonal antibodies (mAbs).
For T-cell subpopulation characterization the following
mAbs were used: allophycocyanin-H7 anti-CD4, fluores-
cein isothiocyanate anti-CD45RA (BD Pharmingen),
peridin-clorophyll protein-Cy5.5 anti-CCR7 (BioLegend,
San Diego, CA), and allophycocyanin anti-CD31 (Milte-
nyi Biotec, Bergisch Gladbach, Germany) mAbs. The
staining was performed for 15 minutes at room
temperature in the dark. Then, red blood cells were
lysed with BD Pharm Lyse™ lysing solution (BD Phar-
mingen). Data were collected immediately using a 6-
colour 2-laser BD FACSCanto II cytometer and analyzed
with the FACSDiva software (BD Biosciences, San Jose,
CA). B- and T-cell subsets were identified (as previously
reported [27-30] and shown in the Additional file 1:
Figure S1) as: CD19+CD10+ immature, CD19+CD10−
IgD+CD27−naive mature, CD19+CD10−IgD−CD27+ mem-
ory switched and CD19+CD10−IgD+CD27+ memory
unswitched B cells; CD4+CD45RA+CCR7+ naive, CD4+
CD45RA+CCR7+CD31+ RTE, CD4+CD45RA−CCR7+ cen-
tral memory (TCM) and CD4
+CD45RA−CCR7− effector
memory (TEM) T cells. The level of cell surface expression
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intensity (MFI) of PBMCs incubated with anti-CD4 and
phycoerythrin-Cy7 anti-CD127 (eBioscience, San Diego,
CA) mAbs.
Statistical analysis
Univariate comparisons between log KREC, log TREC,
IL-7, and IL-7Rα means, calculated in group I, II and III
(and reported in the manuscript along with their stand-
ard deviation), were performed by ANOVA followed by
the Student-Newman-Keuls test for all the pairwise
comparisons, whereas changes of their mean values over
the follow-up were assessed by repeated measure
ANOVA, followed by Bonferroni-corrected multiple
tests. A mixed-model ANOVA for repeated measures
was used to compare the between-group differences in
TRECs, KRECs or CD4 during the follow-up time, and
planned orthogonal contrasts (with Bonferroni-corrected
p-values) were performed to compare the group means
at the time points of interest. Spearman’s rank correl-
ation coefficients were used to assess the correlations of
the immunological parameters with age. To evaluate the
impact of the immunological and virological parameters
on therapy-induced KREC or TREC changes in patients
of group I, two multivariable linear regression models
were fitted, after performing univariable linear regres-
sions aimed at identifying significant factors and at ex-
cluding confounding ones. The differences between the
log-value of KRECs/mL and TRECs/mL found at T72
and T0 were chosen as the dependent variables. As inde-
pendent variables were tested the basal levels of several
immune parameters that could have affected the im-
mune recovery, as listed in Table 2. As a result, the fol-
lowing covariates, whose p-value resulted at least < 0.10,
were chosen as predictors in the final multivariable
models: the pre-therapy level of log KRECs/mL or log
TRECs/mL (which were included in order to adjust for
their potential confounding value), the infection dur-
ation (estimated from the presumed time of infection,Table 2 Univariate regression modelling KRECs and TRECs ch
T72-T0 log K
co
log KRECs/mL at T0 −0.39 [
log TRECs/mL at T0
Age at T0 0.000488
Viremia at T0 (log DNAcopies/mL) 0.07 [
CD4 at T0 (cells/mL) 0.000225 [
CD4/CD8 at T0 0.548
Therapy arm 0.156
Infection duration before therapy start (years) −0.105 [−
HCV coinfection −0.131
95% confidence intervals are in square brackets; n.i.: not included in the model; * pwhich corresponds to the date of the first positive HIV-1
test), the pre-therapy viremia, and the pre-therapy
CD4+/CD8+ cell ratio. The CD4+ cell count was excluded
because it was highly correlated to the CD4+/CD8+ cell
ratio. Accordingly, the obtained multivariable regression
coefficients represented the variation of log KREC or log
TREC differences from T72 to T0, per unit change of the
listed independent variables (Table 3); their values are
reported in the manuscript, after anti-log transformation,
as the percent change of log KREC or log TREC T72-to-
T0 variations. The Kruskal-Wallis test, followed by the
Dunn’s post-hoc test, was employed to compare flow
cytometry results, which are reported herein as medians
and depicted as box-and-whisker plots. Unless otherwise
specified, the criterion for statistical significance was set
at p < 0.05.
Results
Quantification of KRECs and TRECs
The number of KRECs and TRECs of HIV-1-infected
patients (group I: subjects treated with cART and fol-
lowed up for 72 months; group II: HIV-1-infected
patients naive for therapy) was compared to that of
matched HIV-1 uninfected controls (group III). KRECs
of patients of group I at T0 (4.15 ± 0.37 log KRECs/mL)
were similar to those of group III (4.13 ± 0.27 log
KRECs/mL) and significantly higher than those of group
II (3.94 ± 0.35 log KRECs/mL, p < 0.05; Figure 1A). In
addition, the number of KRECs found at T0 was not
modified by 6 or 12 months of therapy (T6: 4.09 ± 0.42,
T12: 4.07 ± 0.39 log KRECs/mL, p =NS), while the long-
lasting treatment resulted in a significant decrease in
new B-cell release from the bone marrow (T72:
3.84 ± 0.49 log KRECs/mL, p< 0.01), so that KREC+ cells
of group I at T72 became significantly lower than those
of group III (p < 0.05), but remained similar to those of
group II (p =NS). The number of KRECs was not corre-
lated with increasing age in any of the groups (data not
shown), while only in group I it was positively correlatedange from T0 to T72
RECs/mL difference T72-T0 log TRECs/mL difference
efficient coefficient
−0.795,0.0155]* n.i.
n.i. −0.67 [−0.826,−0.514]{
[−0.0297,0.0307] 0.00908 [−0.0367,0.0549]
−0.136,0.276] −0.0774 [−0.378,0.223]
−0.00117,0.00162] −0.00171 [−0.00363,0.000212]*
[−0.451,1.55] −1.88 [−3.18,−0.585]†
[−0.196,0.507] −0.0792 [−0.594,0.435]
0.163,−0.0471]† −0.0753 [−0.172,0.0217]
[−0.634,0.372] −0.470 [−1.141,0.200]
<0.10; † p <0.01; { p <0.001.
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Figure 1 Quantification of KRECs and TRECs. (A) Number of KREC+ lymp
followed up for 72 months (group I, from T0 to T72), in 22 HIV-1+ patients
matched uninfected subjects (group III). (B) Number of TREC+ lymphocytes
circles, and dashed significance lines indicate the results of the longitudina
the follow-up in HIV-1+ patients of group I divided according to their CD4+
lines; and≥ 200/μL: filled symbols, solid lines). The lines (in gray for CD4+ c
KRECs and TRECs, or by triangles, as in the case of CD4+ cells); error bars in
Table 3 Multivariable regression coefficients of covariates
predicting KREC and TREC changes from T0 to T72
T72-T0 log KRECs/mL
difference
T72-T0 log TRECs/mL
difference
coefficient coefficient
log KRECs/mL at T0 −0.473 [−0.775,−0.172]† n.i.
log TRECs/mL at T0 n.i. −0.558 [−0.724,−0.391]{
Viremia at T0
(log DNAcopies/mL)
n.i. −0.211 [−0.373,−0.0482]†
CD4/CD8 0.868 [0.155,1.58]† −0.769 [−1.6,0.057] *
Infection duration
before therapy start
(years)
−0.111 [−0.16,−0.0629]{ −0.0648 [−0.118,−0.0121]†
R-squared 0.568 0.820
95% confidence intervals are in square brackets; n.i.: not included in the
model. * p <0.10; † p <0.01; { p <0.001.
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(T0; r = 0.38; p < 0.05) and after 6 months of therapy (T6;
r = 0.51; p < 0.01), but not after one year of treatment
(T12) or at the end of the follow-up (T72).
The number of TREC+ cells, before starting cART, was
significantly lower in group I than in both control group
II and III (2.67 ± 0.87 log TRECs/mL vs. 3.53 ± 0.37 log
TRECs/mL, p < 0.05 and vs. 3.71 ± 0.55 log TRECs/mL,
p < 0.05; Figure 1B), and no correlation between TRECs
and patient age was observed in this group (data not
shown). In contrast, and also differently from KRECs,
TRECs decreased with older age both in group II
(r =−0.62; p < 0.001) and in group III (r =−0.46;
p < 0.001), with an average TREC+ cell loss of 55% every
10 years. Moreover, the number of TREC-containingµ
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lated to the number of CD4+ cells at T0 (r = 0.57
p < 0.01), T6 (r = 0.40; p < 0.01) and T12 (r = 0.41;
p < 0.01), but not at T72. An increase of TREC+ cell pro-
duction in group I was already evident at 6 months of
therapy (T0: 2.67 ± 0.87 log TRECs/mL vs. T6:
3.09 ± 0.59 log TRECs/mL, p < 0.001) and persisted also
after the long-lasting treatment (T72: 3.22 ± 0.44 log
TRECs/mL, p < 0.01), but it never reached the levels
observed in control group II or III (3.53 ± 0.37 log
TRECs/mL and 3.71 ± 0.55 log TRECs/mL, respectively;
p < 0.05). A similar pattern of TREC modulation was
observed if TRECs were calculated per 106 PBMC (see
Additional file 1: Figure S2A); furthermore, the fold
change increases from T0 to T6, T12 and T72 were
comparable when TRECs were expressed in either forms
(see Additional file 1: Figure S2B). Because patients of
group I had a heterogeneous number of CD4+ cells that,
at T0, was correlated to KREC and TREC levels, they
were stratified into two groups: patients with a CD4+ cell
count lower (21 out 36) or higher (15 out 36) than 200
cells/μL. While KRECs did not show a different trend in
the two groups at any time point (Figure 1C), the level
of TREC was differentially modulated, with a pattern not
reflecting that of CD4+ cell increase. Indeed, at T0,
TRECs of patients with CD4+ cells < 200/μL were the
lower (2.21 log TRECs/mL vs. 2.99 log TRECs/mL,
p < 0.001), but at T72 they increased up to the level
found in patients with CD4+ cells > 200/μL (3.20 log
TRECs/mL vs 3.22 log TRECs/mL, p =NS), whose
TRECs, on the other hand, had remained substantially-3 
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Figure 2 Quantification of IL-7 and IL-7Rα mRNA and IL-7Rα cell surfa
patients that initiated cART and were thereafter followed up for 72 months
therapy (group II), and of 11 uninfected subjects (group III). Values measure
lines indicate the results of the longitudinal analysis within patients of grou
and III. Values measured in individual patients are shown as clear squares. (
subjects as determined by flow cytometry; statistical analysis performed byunchanged (Figure 1D). In contrast, the total CD4+ cell
count grew very similarly in the two groups, thus
remaining significantly different at all time points
(p < 0.001; Figure 1D).
Measure of IL-7 and IL-7Rα
To evaluate whether IL-7 and IL-7Rα could be involved
in the modulation of KRECs and TRECs of cART treated
patients, we quantified the RNA of the two targets by
real-time PCR in 10 patients of group I. These cART-
treated patients showed a wide range of IL-7 RNA
values: the mean level of IL-7 RNA relative expression,
which, before therapy, was significantly higher than that
of subjects of group II and III (T0: 3.26 ± 1.53 vs. group
II: 0.69 ± 0.96, p < 0.001; and vs. group III: 1.32 ± 0.52,
p < 0.001), further increased after six months, but then
decreased to reach the levels observed in both groups II
and III after 6 years of therapy (T72: 0.81 ± 1.17,
p < 0.001; Figure 2A). The levels of RNA for IL-7Rα in
group I were also highly heterogeneous at the first two
time points of the follow-up, then the range of values
tended to narrow at the following time points, but their
mean value did not significantly change over time, nor
there were any significant differences in comparison to
that of patients of group II and controls of group III at
any time point. However, the mean IL-7Rα RNA level
was lower in patients of group II than in group III
(0.16 ± 1.03; 1.16 ± 0.47, p < 0.05; Figure 2B). Further-
more, the level of IL-7Rα cell surface expression, calcu-
lated as the MFI of anti-CD127 mAb on CD4+ T cells,
was lower in the patients treated for 6 years with cART mRNA 
II III 
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8 
10 
M
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 (1
03
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II III I 
C 
surface IL-7R  on CD4+ cells 
p < 0.05 
p < 0.01 
ce expression. (A) Quantification of IL-7 mRNA in PBMCs of 10 HIV-1+
(group I, from T0 to T72), of 18 HIV-1+ patients that did not require
d in individual patients are shown as clear circles. Dashed significance
p I. (B) RNA expression of IL-7Rα in PBMCs of patients of groups I, II
C) Surface expression of IL-7Rα on CD4+ cells in the three groups of
ANOVA followed by the Bonferroni test.
Quiros-Roldan et al. Journal of Translational Medicine 2012, 10:94 Page 7 of 11
http://www.translational-medicine.com/content/10/1/94than in patients of group II and subjects of group III
(5630 ± 1250 vs. 6157 ± 1498 vs. 7300 ± 1375 MFI;
Figure 2C), even though the difference was significant
only in comparison to group III (p < 0.01). These data
are in agreement with those indicating that HIV-1 infec-
tion is associated with decreased IL-7Rα expression on
circulating T cells, and effective antiretroviral therapy
only partially restores this defect [31,32].
Identification of factors influencing KREC and TREC
production
To better assess how the immunological or virological
parameters affected the observed therapy-induced KREC
or TREC changes, we employed the linear regression
analysis. First, a series of univariable regressions were fit-
ted in order to identify significant covariates and puta-
tive confounding variables. Results showed that a lower
increase of log TRECs/mL from T0 to T72 is to be
expected in the presence of a higher basal log TRECs/
mL or of a higher CD4+/CD8+ ratio at T0, and that
greater log KRECs reductions could be ascribed to
longer infection duration before therapy initiation. Of
note, neither the different therapy arm nor the presence
of HCV co-infection affected KREC and TREC changes
(Table 2).
The effects of these variables were then reciprocally
adjusted by fitting multivariable regressions (Table 3),
which, after anti-log conversion of the obtained coeffi-
cients, indicated that the TREC increase over time was
72% lower for each additional 1-log of basal TREC value
and 38% lower for each 10-fold increase of blood HIV-
1-RNA. At the same time, a higher basal level of log
KRECs/mL accounted for a stronger reduction in the re-
lease of new B cells from the bone marrow following the
cART, in the amount of a 66% decrease for each add-
itional 1-log of basal KRECs/mL, whereas higher basal
CD4+/CD8+ ratios determined a tapering of KREC de-
crease in the measure of 22% for each 0.10-higher CD4+
/CD8+ ratio. Furthermore, for any additional year of in-
fection duration at the moment of therapy start, the de-
crease of KRECs from T0 to T72 was enhanced by 23%,
whereas the increase of TRECs was reduced by a further
14%.
Cytofluorimetric analysis of B- and T-cell subsets
The percentage (Figure 3A) and number (Figure 3B) of
B- and T-cell subsets were determined by cytofluori-
metric analysis on fresh blood samples of the HIV-1-
infected patients of group I obtained after 72 months of
therapy, which were compared to those of subjects of
group II and group III. Patients of group I had a lower
percentage of immature B cells with respect to those of
group II (6.0% vs. 12.1%, p < 0.05), a percentage and
number of naive and memory switched B cells similar tothose of the other two groups (p =NS) and a lower per-
centage of memory unswitched B cells in comparison to
that of individuals of group II and III (12.54% vs. 16.2%
vs. 22.0%, respectively, p < 0.05). Within the T-cell com-
partment, the percentage, but not the number, of naive
cells and of RTE, which are the cells that were recently
released from the thymus, was lower in group I than in
group II (23.4% vs. 33.4%; p < 0.05), but similar to that of
group III (29.0%; p =NS). Since changes in proliferation
or loss rate occurring within naive and RTE cells may
interfere with the measure of thymic export, the number
of TRECs within naive and RTE populations of un-
treated patients of group I and II was evaluated. As
shown in the Additional file 1: Figure S3A, TRECs were
not different (p =NS) in the two T-cell subsets. Further-
more, the slope and intercept of the regression lines,
obtained by fitting a model with TRECs/mL as
dependent variable and naive/mL or RTE/mL as inde-
pendent variables, were similar (see Additional file 1:
Figure S3B). Therefore, it is likely that no significant var-
iations occurred in the number of naive and RTE cells
that would induce a misinterpretation of TREC data.
Patients of group I showed a significantly higher per-
centage and number of TCM lymphocytes in comparison
to those of group II subjects (43.5% vs. 27.1%, p < 0.05;
and 265 cells/μL vs. 175 cells/μL, p < 0.05; Figure 3A, B),
who, in turn, had a significantly lower percentage and
number of these cells in respect to the healthy indivi-
duals of group III (27.1% vs. 40.5%, p < 0.05; and 175
cells/μL vs. 255 cells/μL, p < 0.05). No significant differ-
ences were observed for TEM cells in the three groups.
Discussion
The extent of thymic output is one of the most import-
ant markers of the T-cell immune recovery in HIV infec-
tion, but this information remains incomplete if not
complemented with the assessment of B-cell compart-
ment that is known to be also impaired during HIV in-
fection. Indeed, in HIV-1-infected individuals, the loss of
memory B cells, together with an altered differentiation
of naive B cells, results in the production of a low quan-
tity of antigen specific antibodies [33]. However, given
the various B-cell sources, routine serotyping does not
allow discrimination between antibodies produced by
newly developed B cells and those produced by old ma-
ture B cells that have been expanded in the periphery. If
the antibody production is solely based on expanding
mature B cells, antibody production will end as the old
B cells die off. Therefore, the integrity and efficacy of re-
generation of the B-cell compartment in HIV+ patients
should also be monitored by distinguishing newly pro-
duced B cells from the old ones. We had previously vali-
dated a method based on the quantification of KRECs
and TRECs which appears to provide a reliable
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[23,24]. Thus, we applied the KREC/TREC assay to
monitor the immunoreconstitution of HIV-1+ patients.
Following what suggested by Ribeiro and Perelson [34]
and Lorenzi et al. [35], we expressed the results of our
analysis in terms of KRECs/TRECs per mL of blood in
order to overcome the bias related to the extensive per-
ipheral cell divisions that would dilute TREC content
and make any KREC/TREC values calculated “per 106
unsorted PBMCs” difficult to interpret, in particular insubjects with a chronic immune activation and increased
peripheral lymphocyte proliferations, such as HIV-
infected patients.
While patients of group I at T0 and of group II
were all not undergoing cART, different levels of
KRECs and TRECs were found in the two groups.
However, these patients represent two different types
of naive subjects because those of group II still main-
tained a quite conserved immune system (CD4+ cell
count >350/μL) and did not need antiretroviral therapy
Quiros-Roldan et al. Journal of Translational Medicine 2012, 10:94 Page 9 of 11
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and treatment of HIV-1 infection, whereas those of
group I at T0 were patients with a number of CD4+ T
cells <350/μL or with clinical AIDS-defining conditions
at diagnosis. They were diagnosed with HIV-1 infec-
tion when the disease had already progressed to a se-
vere level of immune deterioration, so that after
starting antiretroviral therapy and despite full viral
suppression, some of them showed a suboptimal im-
mune recovery.
We also found that the kinetics and the timings of B-
and T-cell release from the bone marrow and thymus
during cART are completely different. KREC production,
that remains unchanged until one year of therapy,
decreases following prolonged therapy to levels that
were similar to those of therapy-free HIV-1+ patients,
but lower than those of uninfected subjects. This result
is not unexpected since it has been previously demon-
strated that, in patients with idiopathic CD4+ lymphocy-
topenia, the percentage of immature/transitional B cells,
that are known to contain the highest number of KRECs
[36], is inversely correlated with the CD4+ T-cell count
[37]. Accordingly, in our patients, the lowest levels of
KRECs were observed in the long-lasting treated patients
who also showed the higher CD4+ lymphocyte count.
Furthermore, in patients with idiopathic CD4+ lympho-
cytopenia, the expansion of immature/transitional B cells
appears to be associated with elevated serum levels of
IL-7 [37]. Previous studies have shown a significant in-
crease of IL-7 level also in lymphopenic states due to
HIV-1 infection and currently there are ongoing clinical
investigations on IL-7 as a potential anti-HIV therapy
[38,39]. In HIV-infected patients, the administration of
IL-7 increases in the proportion of immature/transi-
tional B cells [39]. Thus, the low release of B cells from
the bone marrow we have observed in our patients after
prolonged cART may be related to the levels of IL-7
that, although being very high in the patients that
initiated cART, progressively decreased to levels compar-
able to those observed in patients not requiring therapy
and healthy controls. Therefore, since we also found that
prolonged cART induces an increase of thymic output,
the concomitant administration of cART and IL-7 may
represent a novel strategy for improving the immune re-
constitution in chronic HIV infection. In this regard,
KREC and TREC quantification could be a useful tool
for monitoring the efficacy and safety of IL-7-based ther-
apies [40]. In addition, the observed decrease of memory
unswitched B cells (feature that completes data by
Chong et al. [41], reporting a decline in total memory B
cells), together with the decline in new B-cell produc-
tion, is likely to contribute to the reduced humoral im-
mune response observed in HIV-1+ patients despite
antiretroviral treatment.As already reported by several authors [42,43], we
found that TREC production was increased following
cART initiation, reached a plateau after 12 months, and
remained stable during several years of therapy, although
never reaching the levels observed in the HIV-1-infected
patients not requiring therapy or in the uninfected con-
trols. We also observed the known dependency of
TRECs on ageing [35] only in HIV-uninfected controls
and in the HIV-1-infected patients that did not need
therapy, but not in those who underwent cART. This is
likely to be due to an incomplete immune reconstitution
as indicated by the persistent low number of CD4+ cells
found in several patients of this group. Furthermore, the
increase in TRECs appears to be more evident in
patients with a lower viral load, a lower CD4+/CD8+
ratio, or lower CD4+ cell counts before therapy begin-
ning. In particular, before cART, TRECs were signifi-
cantly lower in those patients with CD4+ cells < 200/μL
than in those with CD4+ cells > 200/μL, although they
increased only in the patients with low CD4+ cells, so
that the difference was abolished after prolonged ther-
apy. The two anti-viral drug combinations appear not to
affect the extent of new B- and T-cell mobilization that,
on the contrary, was affected by the duration of the in-
fection before therapy initiation. Indeed, each year of in-
fection before therapy weakens the recovery of TRECs
and favors the decrease of KRECs observed in most
patients after treatment. While it has been previously
reported that the early initiation of an antiretroviral
therapy restores the memory B-cell number, though only
temporarily [44,45], to our knowledge this is the first re-
port linking the extent of B- and T-cell release from the
production site following long-lasting antiretroviral ther-
apy to the duration of HIV-1 infection before treatment
initiation.
Flow cytometry results partially overlap those obtained
by real-time PCR, because they confirm the lower levels
of immature B cells, which are, for the most part, re-
cently produced B cells, and of naive and RTE T lym-
phocytes in long-lasting treated patients in respect to
patients that did not need therapy (but only if calculated
as percentage and not as total number). Furthermore,
the increase of TCM cells already observed by Hodge
et al. [46] after 2 years of antiretroviral therapy, seems to
persist also after long-lasting treatment.
Conclusions
In conclusion, the analysis of KRECs and TRECs appears
to be a valuable aid for the fine immunological
characterization of HIV-1+ patients treated with cART.
Furthermore, because the administration of recombinant
IL-7 in humans increases the number of TREC-
containing cells [47] and high IL-7 serum levels appear to
be associated with the expansion of immature/transitional
Quiros-Roldan et al. Journal of Translational Medicine 2012, 10:94 Page 10 of 11
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useful for the monitoring of IL-7 based therapies.
Additional file
Additional file 1: Contains Figure S1, S2, and S3 (legend and
artwork).
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